Results 91 to 100 of about 28,601 (275)

Ictal dancing following right temporal seizure onset—Evidence for a distributed network

Epileptic Disorders, EarlyView.
Leo Y. Zhang, German Garza‐Garcia, Alex Doyle, Irfan S. Sheikh   +3 more
wiley   +1 more source

Monotherapy for partial epilepsy: focus on levetiracetam

, 2008
Antonio Gambardella1,2, Angelo Labate1,2, Eleonora Colosimo1, Roberta Ambrosio1, Aldo Quattrone1,21Institute of Neurology, University Magna Græcia, Catanzaro, Italy; 2Institute of Neurological Sciences, National Research Council, Piano Lago di ...
Angelo Labate, Antonio Gambardella, Roberta Ambrosio, Eleonora Colosimo, Aldo Quattrone   +4 more
core  

De novo TANC2 stop‐loss variant associated with developmental impairment and drug‐resistant epilepsy

Epileptic Disorders, EarlyView.
Matthew A. Hintermayer, Kenneth A. Myers
wiley   +1 more source

Levetiracetam en el tratamiento convulsivo canino. Reporte de caso

, 2016
Seizures are one of the most difficult symptoms to control during intoxication because many drugs used have severe effects on the patient's behavior and significantly affect their mental state.
Duque-Muñoz, Leonardo, Molina-Díaz, Víctor Manuel   +1 more
core   +1 more source

NMDAR‐antibody encephalitis: Seizure semiology and EEG findings

Epileptic Disorders, EarlyView.
Abstract Background N‐methyl‐D‐aspartate receptor antibody encephalitis (NMDAR‐Ab‐E) is an autoantibody‐mediated disorder, characterized by acute development of neuropsychiatric symptoms, seizures, movement disorders, and autonomic instability. Objectives To describe acute seizure semiology and electroencephalogram (EEG) findings in patients with a ...
Maria Emilia C. Andraus, Bernard Liem, Sidra Aurangzeb, Mkael Symmonds, Adam E. Handel, Sarosh R. Irani, Arjune Sen   +6 more
wiley   +1 more source

Pharmacotherapy of Epilepsy: Focus on Levetiracetam

, 2009
Levetiracetam is a second-generation antiepileptic drug which first came to the United States market in 1999. It has a mechanism of action that is not well elucidated.
Allison M. Chung, Molly E. Adams, Lea S. Eiland   +2 more
core   +1 more source

Maternal and umbilical cord plasma concentrations of antiseizure medications: Results from the observational MONEAD study

Epilepsia, EarlyView.
Abstract Objective Unanticipated changes in antiseizure medication (ASM) exposure can lead to subtherapeutic or toxic medication concentrations in the mother and unnecessary drug exposure for the fetus. The objectives of this study were to characterize ASM concentrations in mother's and cord blood at delivery in women with epilepsy (PWWE).
Charul Avachat, Kimford J. Meador, Page B. Pennell, Angela K. Birnbaum, MONEAD Investigator Group, Delmaris Acosta‐Cotte, Sandra Alhaj, Stephanie Allien, Taimur Anwar, Anto Bagic, Gregory L. Barkley, Donald Bearden, Susan Beers, Irena Bellinski, Christin Bermudez, Kristina Blessing, Katrina Boyer, Camilla Casadei, Patricia Chang, Li Chen, Andrea Cheng‐Hakimian, Melanie Choe, Kirsten Cleary, Tobi Clements, Joseph Coda, Pam Coe, Jules Constantinou, Yael Cukier Cukier, Danielle Culbreth, Elizabeth Cunningham, Kayla Darris, Lisa Davis, Rosemarie Delucca, Jennifer DeWolfe, Jessica Dimos, Mary Dolan, Maurice Druzin, Joyce Echo, Sarah Ellis, Pedro Figueredo, Richard Finnell, Kellie Flood‐Schaffer, Jacqueline French, Mark Friedman, Shailaja Gaddam, Satya Gedela, Elizabeth Garard, Christine Ghilian, William Grobman, Cheryl Hall, Ellen Hanson, Jacqueline Helcer Helcer, Paige Hickey, Gregory Holmes, Theresa Holmes, Dominic Ippolito, George Jewell, Arundhathi Jeyabalan, Emily Johnson, Michelle Kim, Gregory Krauss, Casey Krueger, David Labiner, Hadley Lange, Erin Latif, Connie Lau Lau, Shari Lawson, Brenda Leung, William MacAllister, James Maciulla, Hayley Madeiros, Nazin Mahmood, Jennie Mao, Ryan May, Paul McCabe, Frederick T. McElrath, Erica Meltzer Meltzer, Lucy Mendoza, Emily Miller, John W. Miller, Michelle Miranda, Jennifer Moon, Eugene Moore, Melissa Morris, Chris Morrison, Lorene Nelson, Melanee Newman, Alisha Olson, Kim Ono, John Owen, Alison Pack, Michael Paglia, Yong Park, Lamar Parker, Christina Patterson, Sonia Perez, Jenny Pohlman, Alison Pritchard, Michael Privitera, Krestin Radonovich, Patty Ray, Katie Reger, Gustavo Rey, Matthew Ryan, Yasin Salih, Carla Sandles, William Schweizer, Jordan Seliger, Enrique Serrano, Nilay Shah, Elizabeth Shashkova, Traci Sheer, Yvonne Sheldon, Rachel Sierra, Marianna Spanaki‐Varelas, Anna Steele, Jennifer Steele, Alice Stek, Zachary Stowe, Jolie Strauss, Suzanne Strickland, Melissa Sutcliffe, Hima Bindu Tam Tam, Diane Teagarden, Andrea Thomas, Matthew Thompson, Jeffery Tsai, Alexandra Urban, Linda Van Marter, Naymee Velez‐Ruiz, Yue Wang, Vibhangini Wasade, Taylor Weinau, Peter Wells, Carrie Wiles, Mark Yerby, Amy Young, Andrew Zillgitt, Annette Zygmunt   +138 more
wiley   +1 more source

Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age

, 2013
Justine Cormier, Catherine J ChuMassachusetts General Hospital, Department of Neurology, Programs in Child Neurology and Neurophysiology, Boston, MA, USAAbstract: Epilepsy is a common neurological disorder in the pediatric population, affecting up to one
Cormier J, Chu CJ
core  

A star in the daylight clinical vignette: Lesional focal epilepsy with cerebral accessory falx

Epileptic Disorders, EarlyView.
Kyle McGrath, Joel Kaye, John Paul Sheehy, Heather Ravvin McKee   +3 more
wiley   +1 more source

Ranking of antiseizure medications in a panel of focal seizure models predicts their comparative efficacy in clinical add‐on trials in drug‐resistant focal epilepsy

Epilepsia, EarlyView.
Abstract Objective Most antiseizure medications (ASMs) have been discovered by testing in animal models, which are generally thought to predict antiseizure activity in patients. However, it is not known whether any of these models (or a combination of models) can predict whether a novel ASM exhibits higher clinical efficacy in focal drug‐resistant ...
Wolfgang Löscher, Pavel Klein
wiley   +1 more source